Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indoco Yet To See Predicted Revival In Domestic Business

As Company Reports 18% Revenue Growth Overall In Q3

Executive Summary

India’s Indoco has reported double-digit growth despite a slow recovery of its domestic business during its financial third quarter ended 31 December 2020. The Indian company reported 18% sales growth overall, lifted by 73% growth in its International business in Q3. 

You may also be interested in...



Indoco Counts On Indian Market Bouncing Back

Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump.  The Indian company continues to perform well internationally and grow overall.

Nippon Chemiphar Is Managing To Slow Its Decline

Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast. 

Who’s Hired? ANI Pharma Strengthens Leadership With Three New Executives

ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel